Patterson Companies reported a decrease in net sales by 2.7% year-over-year to $1.57 billion for the third quarter of fiscal 2025. Diluted GAAP earnings per share were $0.35, down from $0.52 in the prior year, and adjusted earnings per share were $0.43, compared to $0.59 in the prior year. Both GAAP and adjusted earnings were negatively impacted by a cybersecurity attack on Change Healthcare.

Patterson Companies reported a slight increase in net sales for the fourth quarter of fiscal year 2024, with strong performances in dental consumables and production animal businesses offsetting declines in other areas. The company's GAAP earnings were $0.74 per diluted share, while adjusted earnings were $0.82 per diluted share, both negatively impacted by the Change Healthcare cybersecurity attack.

Patterson Companies reported a 1.0% increase in net sales to $1.62 billion. GAAP earnings were $0.52 per diluted share, and adjusted earnings were $0.59 per diluted share. The company returned $148.8 million to shareholders through dividends and share repurchases and revised fiscal 2024 GAAP earnings guidance to $1.99 to $2.04 per diluted share and adjusted earnings guidance to $2.30 to $2.35 per diluted share.

Patterson Companies reported a 1.6% increase in net sales to $1.65 billion and GAAP earnings of $0.42 per diluted share for the second quarter of fiscal year 2024. The company's performance was driven by strong dental consumables growth, offset by lower sales in certain high-tech dental equipment categories. The Animal Health segment benefited from a diverse offering and omnichannel presence.

Patterson Companies reported a 3.5% increase in net sales to $1.6 billion and a 2.8% increase in internal sales for the first quarter of fiscal 2024. GAAP earnings per diluted share were $0.32, while adjusted earnings per diluted share increased 25% to $0.40. The company reaffirmed its fiscal 2024 earnings guidance.

Patterson Companies reported a 5.0% increase in net sales to $1.72 billion for the fourth quarter of fiscal 2023, with internal sales increasing by 5.7%. GAAP earnings were $0.77 per diluted share, and adjusted earnings were $0.84 per diluted share, an 18% increase year-over-year. The company also issued fiscal 2024 GAAP earnings guidance of $2.14 to $2.24 per diluted share and adjusted earnings guidance of $2.45 to $2.55 per diluted share.

Patterson Companies reported a strong fourth quarter with net sales of $1.64 billion, a 4.9% increase compared to the same period last year. GAAP earnings were $0.65 per diluted share, and adjusted earnings were $0.71 per diluted share. The company's performance was driven by growth in both Dental and Animal Health segments.

Patterson Companies reported a 2.9% increase in net sales to $1.6 billion and a 4.3% increase in internal sales. GAAP earnings were $0.58 per diluted share, while adjusted earnings were $0.55 per diluted share. The company raised its fiscal 2022 GAAP earnings guidance to $1.86 to $1.91 per diluted share and adjusted earnings guidance to $2.08 to $2.13 per diluted share.

Patterson Companies reported a 6.2% increase in net sales to $1.65 billion and GAAP earnings of $0.49 per diluted share for the second quarter of fiscal year 2022. The company has increased its fiscal year 2022 GAAP earnings guidance range to $1.69 to $1.79 per diluted share and adjusted earnings guidance range to $2.00 to $2.10 per diluted share.

Patterson Companies reported a strong start to fiscal 2022, with net sales increasing by 29.6% year-over-year to $1.61 billion. Adjusted earnings per share increased by 30% over the prior year. The company raised the lower end of its adjusted EPS guidance range, reflecting continued momentum and confidence for the remainder of the year.

Patterson Companies reported a 21.4% increase in fourth-quarter net sales to $1.56 billion and GAAP earnings of $0.30 per diluted share. The company's internal sales increased by 23.5%.

Patterson Companies reported a 6.5% increase in net sales to $1.55 billion and a 23.4% increase in adjusted EPS to $0.58 per diluted share for the third quarter of fiscal year 2021. The company's performance was driven by strong sales execution and improved operating margins in both the Dental and Animal Health segments.

Patterson Companies reported a 9.5% increase in net sales to $1.55 billion and adjusted earnings per diluted share of $0.63, a 62% increase year-over-year, reflecting strong sales execution and expense discipline.

Patterson Companies reported a decline of 6.2% in consolidated net sales, totaling approximately $1.25 billion for the first quarter of fiscal 2021. Despite challenges due to COVID-19, the company delivered year-over-year adjusted earnings growth of 22%.

Patterson Companies reported a decrease in consolidated net sales by 10.5% to $1.29 billion due to COVID-19 disruptions, with a net loss of $608.6 million. However, adjusted net income increased by 16.2% to $41.1 million, driven by strong sales momentum early in the quarter and cost-saving measures.

Patterson Companies reported a 4.3% increase in net sales to $1.46 billion and a rise in adjusted earnings per diluted share to $0.47. The Dental segment showed strong growth, while the Animal Health segment also contributed to the overall positive results. The company has raised its fiscal year 2020 adjusted earnings guidance.